ALVAC-CEA vaccine

ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene.

A phase I trial in 118 patients showed safety in humans.^[1]

References

Development

Classes

Administration

Vaccines

Bacterial	Anthrax Brucellosis Cholera^# Diphtheria^# Hib^# Leptospirosis Lyme disease^‡ Meningococcus^# MeNZB NmVac4-A/C/Y/W-135 Pertussis^# Plague Pneumococcal^# PCV PPSV Q fever Tetanus^# Tuberculosis BCG^# Typhoid^# Ty21a ViCPS Typhus combination: DTwP/DTaP

Viral	Adenovirus Flu^# H1N1 (Pandemrix) LAIV Hantavirus Hepatitis A^# Hepatitis B^# Hepatitis E HPV Cervarix Gardasil Japanese encephalitis^# Measles^# Mumps^# Mumpsvax Polio^# Sabin Salk Rabies^# Rotavirus^# Rubella^# Smallpox Dryvax Tick-borne encephalitis Varicella zoster chicken pox^# shingles (live) Yellow fever^# combination: MMR MMRV research: Chikungunya Cytomegalovirus Dengue Ebola Epstein–Barr virus Hepatitis C HIV

Protozoan	research: Malaria Trypanosomiasis

Helminthiasis	research: Hookworm Schistosomiasis

Other	Cancer vaccines ALVAC-CEA Hepatitis B^# HPV Cervarix Gardasil NicVAX TA-CD TA-NIC

Controversy

This article is issued from Wikipedia - version of the 12/18/2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.